The serotonin theory of platelet-rich thrombus growth
Platelets are the richest source of serotonin in the body outside the brain.
The source of the serotonin is extra-platelet, being acquired by means of the cell membrane serotonin uptake mechanism. Inhibition of this mechanism by serotonin reuptake inhibitors (SSRIs) causes depletion of platelet serotonin [1] . The high concentrations of serotonin located in the dense granules are released upon platelet activation, and act upon platelet serotonin 5HT 2A receptors to activate more platelets, thus constituting a positive feedback or "snowball" mechanism leading to thrombus growth. The serotonin theory [2] [3] [4] [5] supposes that this serotonin mediation is essential for thrombotic occlusion of diseased coronary arteries owing to fact that such occlusion are abolished by antagonism of the platelet 5HT 2A receptor [6, 7] even when the major stimulus of adrenaline is applied [8] and in the circumstances where thrombolysis has failed to clear a complete thrombotic occlusion [9] . Examination of patients undergoing angiography showed that a high serotonin level was significantly associated with coronary artery disease in patients younger than 70. In nearly four years of follow up high serotonin levels were also associated with cardiac events. This association persisted after adjustment for conventional risk factors [10] . 5HT 2A antagonism was advocated in the treatment of coronary artery disease [11] in which some positive preliminary results were published [3] A further aspect of the theory relevant to such a proposal concerns the fact that serotonin is not present in the arterial wall or tissues and does not participate in the mediation of haemostatic platelet layers. Thus, platelet-rich thrombus growth which can cause myocardial infarction and unstable angina are inhibited, but there are no bleeding side effects as seen with all other antiplatelet therapies. However, by chance, the frequent use of SSRIs to treat depression after acute coronary syndromes (because other antidepressants are cardiotoxic) has led to the realisation that these drugs also reduce the consequences of platelet-rich thrombus growth. In this case, the benefits arise from the fact that there is less serotonin in the platelets to be released upon activation, and thus there is less serotonin to activate other platelets through their 5HT 2A receptors.
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Serotonin receptors
Serotonin is a neurotransmitter in the central nervous system which directly activates 5HT receptors. Serotonin receptors come in 7 types with numerous subtypes, most of which are associated with the central nervous system. For the purposes of this review we will only examine 5HT 1A , 5HT 1B , and 5HT 2A as these are the most important receptors found outside the central nervous system, where serotonin acts as a local hormone. The multiplicity of receptor subtypes explains the disparate effects of serotonin on the cardiovascular system [12] . Serotonin is released into the plasma from nerves, chromaffin cells and platelets. It is taken up by liver, endothelium and platelets where it is stored in the dense granules ( Figure 1 ). Normal levels of serotonin in plasma are very low and at the limits of measurement techniques [13] . Serotonin release by platelets is the main source of serotonin in the plasma as the platelet contains large amounts of dissolved serotonin; in addition the dense granules have a very high concentration of serotonin. The normal adult platelet concentration of serotonin is 3.81 ± 0.87 nmoles.10 9 platelets [14] .
Serotonin is classified as a weak platelet agonist [15] but, when combined with other agonists of platelet aggregation, amplifies the response. Local concentrations of serotonin in the region of a coronary stenosis, which causes shear stress upon the platelet, are very high and form the basis of the amplification of the platelet activation and aggregation reactions [16] . See and thrombin thus suggesting a major role for serotonin and the platelet serotonin receptor in the genesis of intracoronary thrombosis [17] . See Figure   2 .
The role of serotonin in intravascular thrombosis
The beneficial effects of 5HT 2A receptor blockade in animal models of intracoronary thrombosis have been well shown. Using the Folts model in which a critical stenosis overlies damaged endothelium, 5HT 2A antagonism was effective in abolishing intracoronary platelet-rich thrombosis [6, 7, 18, 19] .
When used as an adjunct to thrombolysis in the Folts model, selective 5HT 2A
blockade improved flow even after withdrawal of the thrombolytic agent and normalisation of coagulation variables and bleeding time, which suggest good safety margins as well as therapeutic effectiveness of this class of agents [9] .
There is also evidence to suggest that 'demand-induced myocardial ischaemia' in the presence of coronary arterial stenosis, involves platelet activation and or microvascular vasoconstriction due to serotonin released from platelets [20] . Both recovery of ST segment change and mechanical function are improved in the presence of 5HT 2A receptor antagonism [20] . 
Pharmacology (a) General
The interest in drugs for the prophylaxis of migraine resulted in the production of pure 5HT 2A antagonists, which turned out to be of no benefit in this condition, but are predicted to be of value in intra-arterial thrombosis (see section on serotonin theory above). During the period of their development, improvements resulted in increased potency of the agents and coincidentally an increasing body of evidence that platelets, the vasculature and serotonin were implicated in coronary artery disease. 5HT 2A antagonists were found to have no effect on migraine but 5HT 1B/1D agonists such as sumatriptan which cause vasoconstriction of the cerebral vasculature are highly effective. They do possess minor systemic vasoconstrictor properties [58] and also minor constrictor effects on the coronary arteries acting through the 5HT 1B subtype receptor in people without coronary artery disease [59] . These effects do not appear to have any clinical significance but coronary artery or vasospastic diseases are contraindications to their use, although Macintyre's study was in patients undergoing diagnostic coronary angiography in which systemic and pulmonary artery pressures were raised and coronary artery vasoconstriction was seen in response to intravenous sumatriptan; heart rate and ECG morphology were unchanged [60] . Studies of receptor sub-types conclude that serotonin-induced contraction of coronary arteries is most probably mediated via the activation of both 5HT 1B and 5HT 2A receptors [61, 62] . Chest pain has been reported following administration of sumatriptan-like drugs and there have been occasional incidences of myocardial infarction even with normal coronaries [63] . However, exercise test abnormalities are rare in patients with sumatriptan-induced chest pain [63] and there is little evidence of any relation to cardiovascular disease [64] .
(b) Development of the use of SSRIs in depression following acute coronary syndromes
The older tricyclic antidepressants possess serious cardiovascular side effects and are contraindicated in depressed patients with an acute coronary syndrome [65] . The use of tricyclic antidepressants, but not SSRIs, is associated with an increased risk of myocardial infarction [66, 67] . On the other hand, SSRIs are well-established antidepressant drugs that have shown little evidence of cardiac toxicity, even in patients with heart disease. The recent Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) studied 364 depressed patients with acute coronary syndromes and documented no evidence of harm with sertraline treatment and showed a (non-significant) trend towards reduction in morbidity and mortality among the SSRI-treated patients [68] . Lower cardiovascular morbidity and mortality in SSRI-treated patients was reported in recent epidemiologic studies [66, 67, 68, 69, 70] . Further, a study of 137 post-stroke patients treated with sertraline who were followed up for one year also showed reduced mortality and morbidity [71] . More trials are required to establish these findings, but should not be confined to patients with depression. Unfortunately, SSRIs take time to deplete serotonin from the platelets, so that they cannot be expected to work at once in an acute coronary syndrome, but only by treatment beforehand. It would therefore be necessary to start with trials of secondary prevention by SSRIs in patients with arterial disease, whether depressed or not.
Depression is a significant risk factor for ischaemic heart and cerebrovascular disease as well as mortality following myocardial infarction [72, 73] . The potential effects of SSRIs upon the cardiovascular system may therefore be very important. A recent study [74] draws attention to a potential benefit from these drugs in hypertensive patients 18 months after myocardial infarction;
episodes of depression (negative affect) and hypertensive responses to depression were reduced in patients who had been prescribed SSRI drugs.
The authors ascribed this decreased response to lessened sympathetic drive and its effects on cardiovascular reactivity [75, 76] , but the investigators did not measure catecholamine levels. Unlike ketanserin (with α 1 adrenoreceptor antagonist properties), pure 5HT 2A receptor antagonists do not affect the blood pressure although it is suggested that serotonin may help maintain the chronic increase in peripheral resistance in hypertensive patients. If so, it could be due to increased responsiveness of the vessel wall to 5HT 1 serotonin-mediated vasoconstriction, and/or a reduced ability to clear serotonin from the blood [29] . Hypertension is, of course, only one of many independent risk factors targeted in secondary prevention following myocardial infarction. All the patients in the quoted study were also receiving aspirin and about half were prescribed ACE inhibitors and/or β-blockers; 80% received nitrates which are also known to suppress blood platelets [77] . In another hypertension study, blockade of the platelet serotonin receptor (5HT 2A receptor) with ketanserin in pregnancy, for the treatment of mild to moderate mid-trimester hypertension, decreased the number of cases of pre-eclampsia and severe hypertension as well as reducing the incidence of placental abruption and perinatal mortality [78] .
Investigation of patients with diabetes and peripheral vascular disease have shown low intraplatelet serotonin levels associated with platelet hyperreactivity [79] , in contrast to the finding of decreased platelet reactivity seen with SSRIs [1] . Possibly this is due to over-release of serotonin from activated platelets, this was reflected in a 66% increase in plasma serotonin levels although these did not reach statistical significance [79] .
Actions of SSRIs in the periphery
The purpose of SSRI drugs is to increase serotonin concentration in the nerve synapses within the central nervous system. This is achieved by prevention of reuptake into the nerve terminal and, because of loss of negative feedback control, there is overproduction of serotonin by the nerve terminal [80] Blood platelets actively take up serotonin from the plasma but are incapable of its synthesis. SSRI drugs reduce the uptake of tritiated serotonin by platelets [81] . This has led to the use of blood platelets as a surrogate for the central nervous system in the study of these drugs [82] . The tricyclic antidepressants such as imipramine have been reported to decrease platelet serotonin concentration but do not inhibit uptake [83] . In a general practice study, in which normal patients were compared to depressive patients, those taking the SSRI drug fluoxetine had significantly decreased aggregatory response to submaximal collagen stimulation [1] ; this study also showed a significant decrease in serotonin concentration in platelet rich plasma associated with use of fluoxetine but not with the tricyclic antidepressant amitryptiline. It is attractive to suggest that lowered platelet serotonin content translates into less serotonin release during platelet activation at an intracoronary stenosis. A study into the effects of paroxetine (SSRI) revealed lower platelet factor 4 (PF 4 ) and β-thromboglobulin (ß-TG) levels and suggests that reduced platelet aggregation in vivo may positively impact upon coronary artery disease-related mortality in this [84] .
Is the mechanism of beneficent action of SSRIs in coronary disease platelet related?
Enhanced platelet activation has indeed been proposed as a possible mechanism contributing to the increased cardiac risk associated with the diagnosis of major depression [85, 86] . Circumstantial evidence is consistent with this prediction. Data have accumulated indicating that depression is associated with platelet activation and that the SSRIs [1, 85, 86] affect platelet function. SSRIs reduce platelet activity in patients on aspirin therapy and in patients with heart failure [87] . Platelet activity is also decreased by in vitro exposure to both sertraline (an SSRI) and N-desmethylsertraline, the nonactive metabolite of sertraline [88] . Does this imply an effect on platelets which is not dependent on serotonin depletion? Paroxetine reduces the abnormality in platelet hyper-reactivity observed in depressed patients [89] .
Patients with major depression exhibit reduction of serotonin transporter platelet binding sites by imipramine [90, 91] and an increase in serotonin 5HT 2A receptor binding sites on the platelet surface [92] , as determined by radioligand binding studies [93] . Enhanced platelet activity is also reflected in markedly elevated β-TG and PF 4 levels in patients suffering from depression and chronic ischemic heart disease [94] . The breakdown of serotonin is dependent on monoamine oxidase, which is increased in depressed patients [95] . Unfortunately, for the clarity of interpretation of modern studies, most patients with acute coronary syndromes are treated with aspirin and/or clopidogrel, but the accumulated evidence is strongly consistent with platelet activation as a major determinant of increased intra-arterial thrombosis in depressed patients.
Can SSRIs reverse platelet activation in patients with arterial disease?
A number of studies have been carried out using the SSRI sertraline which is a potent SSRI and a selective dose-related inhibitor of the serotonin transporter; by this mechanism serotonin 5-HT 2A receptors and other serotonin receptors in the brain are downregulated [96] . As with fluoxetine [1] , sertraline depletes platelet serotonin [82] . There is also a reduction in SSRI radioligand binding [97] . Overall platelet thrombosis as determined in vitro by collagen stimulation is inhibited by sertraline [98] , as is intracellular Ca 
Clinical platelet function testing
Clinical platelet function testing has been fraught with difficulty, but in view of the importance of platelet function in assessment and prognosis, some attempt should be made to standardise methods. Vacutainer ® sampling is unsuitable as suction from a vein through a small bore needle will activate the platelet artefactually. There is considerable disparity in techniques of assessing platelet function. Because of the importance of serotonin in the development and amplification of the platelet aggregatory response, we attempted to mimic the clinical situation as closely as possible by using normocalcaemic whole blood. To maintain normocalcaemia the anticoagulant used is recombinant hirudin; this is a pure thrombin inhibitor which has no intrinsic anti-platelet activity and has been shown to be ineffective when platelets are under conditions of high shear and exposed to collagen [100] . formation and release of ADP and serotonin largely account for platelet aggregation with collagen in vitro, as determined by platelet counting [105] .
Thus, collagen provides a global means of assessing impairment in vitro since these mediators may be altered through several different mechanisms or changes in expression of the integrin receptors involved in adhesion and aggregation, as well as changes in platelet sensitivity to TXA 2 , ADP and adrenaline [105] . This technique has also been applied to investigation of the heparin-induced platelet dysfunction which is encountered clinically and has been demonstrated to be a failure to form large stable aggregates, despite microaggregation being unaffected [106, 107, 108, 109, 110] . Single platelet counting is labour intensive, but many of the simpler tests are unsatisfactory.
Binding of the platelet IIb/IIIa receptor to fibrinogen can be measured using cell cytometry or an automated fibrinogen-binding test using the Ultegra ® rapid platelet function assay (Accumetrics, San Diego, CA, USA).
Unfortunately, these assays have not been used so far with samples anticoagulated with hirudin to maintain normocalcaemia, although there appears to be no technical difficulty in so doing.
The future
To where should research into the effects of SSRIs on patients with vascular disease lead?
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What is the potential for therapeutic intervention involving the serotonin system in non-depressed patients with arterial disease?
Recent confirmation that acute events are associated with activation of the platelet serotonin system was obtained from the fact that excessive transcardiac accumulation of serotonin appears to play a role in the conversion of chronic stable angina to an unstable coronary syndrome [10] .
Blockade of this system during acute coronary syndromes (or acute limb ischaemia) is therefore an obvious therapeutic intervention to be tried. In view of the time required for SSRIs to achieve antiplatelet effects in acute coronary syndromes, it may be difficult to obtain ethical clearance for a comparison of these agents with those that block the serotonin system directly.
In view of the lower platelet serotonin levels reported with SSRI treatment, the evidence of decreased platelet aggregability and the decreased hypertensive responses seen with the use of SSRIs, three lines of research open up:
1. First, monitoring of cardiovascular events should be possible in these patients and can be related to the drugs' antihypertensive effects.
2. Second, the antiplatelet effects of these drugs should be monitored and compared to patients not taking SSRIs. It is now possible reliably to measure platelet function in whole blood 24 hours after sampling; this would allow remote testing of a large number of patients [111, 112] .
3. Third, the possibility of interactions with aspirin and stomach bleeding merits further investigation. It may be that the withdrawal of aspirin could be carried out safely in these patients who would remain protected by their SSRI drug. This of course could be tested by the platelet aggregometry technique as described in the section above. 
